Recent Pfizer Press Releases

  • 4/23/15 2:07 pm EDT

    Declares 28-Cent Second-Quarter 2015 Dividend

    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 28-cent second-quarter 2015 dividend on the company’s common stock, payable June 2, 2015, to shareholders of record at the close of business on May 8, 2015. The second-quarter 2015 cash dividend will be the 306th consecutive quarterly dividend paid by Pfizer. “In 2014, we returned nearly $12 billion to shareholders through dividends and share repurchases,” said Ian Read, chairmanmore...
  • 4/21/15 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that XALKORI® (crizotinib) received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). Occurring in approximately one percent of NSCLC cases1, ROS1-positive NSCLC represents a particular molecular subgroup of NSCLC.2 XALKORI currently is approved in the U.S. for the treatment of patientsmore...
  • 4/21/15 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer today announced that the Phase 3 study investigating the treatment of inotuzumab ozogamicin met its first primary endpoint of demonstrating a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive acute lymphoblastic leukemia (ALL) compared to that achieved with standard of care chemotherapy. The Phase 3 study has two primary endpoints, complete hematologic remission rate andmore...
  • 4/20/15 8:00 am EDT
    • First of several registration trials expected to start in 2015 for the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer
    • Initiation and first patient treated in Phase III clinical study recruiting across approximately 290 sites in more than 30 countries
    • The primary endpoint of the study is overall survival (OS) in patients with programmed death-ligand 1 positive (PD-L1+) stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior platinum-containing doublet therapy
    DARMSTADT, Germany & NEW YORK--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, and Pfizer Inc, New York, US, today announced the initiation and first patient treated in the international Phase III study (EMR 100070-004) designed to assess the efficacy and safety of the investigational cancer immunotherapy avelumab (MSB0010718C), compared with docetaxel, in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who have experienced disease progression after receiving a prior platinum-more...
  • 4/16/15 2:26 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 23. To access the webcast, visit our website at www.pfizer.com/annualmeeting and click on the “Annual Meeting of Shareholders Webcast” link. Information on accessing and pre-registering for the live audio webcast will be available at www.pfizer.com beginningmore...
  • 4/16/15 8:30 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) addresses some challenging questions often posed by shareholders and the public in its latest integrated annual review for 2014. In a series of video Q&As, Pfizer colleagues respond to questions such as: “Why do people say medicines are so expensive?” and “Why is it so difficult to find a cure for cancer?” The 2014 integrated report also highlights a number of partnerships focused on collaborative research andmore...
  • 4/15/15 8:00 am EDT

    Phase 3 Top-Line Results Show IBRANCE in Combination with Fulvestrant Meets Progression-Free Survival (PFS) Primary Endpoint

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 PALOMA-3 trial for IBRANCE® (palbociclib) met its primary endpoint of demonstrating an improvement in progression-free survival (PFS) for the combination of IBRANCE plus fulvestrant compared with fulvestrant plus placebo in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer following disease progression during ormore...
  • 4/9/15 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced the launch of a new competitive grants program the company is funding to support research projects investigating the role of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) in health and cardiovascular disease. This competitive grants program, which is an extension of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Cardiovascular program, is part of Pfizer's ongoing commitment tomore...
  • 2/4/15 8:00 am EST

    Citing the need for more support for metastatic breast cancer patients, Pfizer pledges $500,000 (USD) in funding for international grants program

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced a grant to the Union for International Cancer Control (UICC) for a first-of-its-kind initiative to address the unique challenges facing metastatic breast cancer (MBC) patients. While great progress has been made in the management of breast cancer, it remains a significant and growing global health issue and patients are commonly diagnosed in the advanced stages of the disease.1,2 The Seeding Progress andmore...
  • 1/6/15 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 2:30 p.m. Pacific Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “33rd Annual J.P. Morgan Healthcare Conference” link inmore...